Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Repolarization Study of ABBV-CLS-7262 in Healthy Subjects
NCT06310876Phase 1Completed
- Sponsor
- Calico Life Sciences
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fosigotifator in amyotrophic lateral sclerosis (ALS) and leukoencephalopathy with vanishing white matter (VWM) (4 arms), sponsored by Calico Life Sciences. Primary endpoint: QTc interval up to 24 hours. Started Mar 2024; status: completed.
02
Drugs
fosigotifator
03
Conditions
amyotrophic lateral sclerosis (ALS)leukoencephalopathy with vanishing white matter (VWM)
Beyond the preview
Go deeper on NCT06310876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06310876.